Biobeat

FDA Cleared Cuffless 24-hour Ambulatory Blood Pressure Monitoring

Business Model
B2B
Last Round
Series BDec 2025
Rounds
1

About

Biobeat is revolutionizing hypertension diagnosis and management with FDA-cleared cuffless ambulatory blood pressure monitoring. Its wireless, non-invasive medical-grade chest patch measures 24-hour blood pressure without the stress and inconvenience of traditional cuff methods, giving physicians continuous, accurate data for clinical decisions. The company uses a proprietary patented PPG sensor and a comprehensive monitoring platform so clinicians can track vital signs, reduce misdiagnosis, and support optimal treatment. Biobeat holds regulatory approvals in the United States, Europe, and other markets.

Summary

Biobeat is a Digital Health company based in Israel. Its most recent funding was a Series B round in Dec 2025. Investors include Ally Bridge Group and OrbiMed.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BDec 2025

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Biobeat on Indexed.vc
<a href="https://indexed.vc/companies/biobeat"><img src="https://indexed.vc/api/badge/company/biobeat" alt="Biobeat on Indexed.vc" width="260" height="76" /></a>